Free Trial

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 13 of 20

 
 

Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics logoViking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. Read More 
 
Trailing Twelve Months EPS: ($0.93)
2024 EPS Estimate: ($0.98)
2025 EPS Estimate: ($1.42)

Current Stock Price
$51.99
Consensus Rating
Buy
Ratings Breakdown
12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$109.73 (111.1% Upside)

 

"This Could Be Worse Than the Great Depression, the Dot-Com Crash, and the 2008 Crisis Combined" (Ad)

What Are These Billionaire Investors Afraid Of? Billionaires Warren Buffett, Stanley Druckenmiller, George Soros, and David Tepper have all sold off massive U.S. stock positions, including shares of Nvidia, Apple, and Bank of America. Billionaire Ray Dalio, who runs one of the world’s most successful hedge funds, says, “Things are going to get worse for our economy.” What are these billionaires so worried about?

Click here to see why experts and insiders may be preparing for the biggest financial crisis of the